A Randomized Controlled Noninferiority Trial of Single Dose of Oral Dexamethasone Versus 5 Days of Oral Prednisone in Acute Adult Asthma

Rehrer, Matthew W.; Liu, Bella; Rodriguez, Marcela; Lam, Joseph; Alter, Harrison J.

doi:10.1016/j.annemergmed.2016.03.017

Cited by 25 publications

(49 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…All of the studies were randomized controlled trials. Eleven of the included studies were published in peer‐reviewed journals, while two of the studies were published abstracts . The relapse rates from one study was not included in the analysis due to a lack of information, which the authors were unable to clarify…”

Section: Resultsmentioning

confidence: 99%

“…The majority of studies were published in the United states, followed by Canada, Indonesia, Mexico, and Taiwan . The severity of the asthma exacerbation in the included patients was not reported in the majority of studies .…”

Section: Resultsmentioning

confidence: 99%

“…The severity of the asthma exacerbation in the included patients was not reported in the majority of studies . Some studies summarized it as mild–moderate, moderate–severe, and severe…”

Section: Resultsmentioning

confidence: 99%

“…Prednisone and prednisolone were the most common PO corticosteroids provided followed by dexamethasone, methylprednisolone, and deflazacort . Eight studies assessed a PO lc corticosteroid regimen while four studies utilized a PO sc corticosteroid regimen, with each study providing 5 days of PO prednisone treatment . No studies comparing PO sc versus PO lc corticosteroids could be identified.…”

Section: Resultsmentioning

confidence: 99%

See 3 more Smart Citations

Prioritizing Systemic Corticosteroid Treatments to Mitigate Relapse in Adults With Acute Asthma: A Systematic Review and Network Meta‐analysis

Rowe

Kirkland

Vandermeer

et al. 2017

Academic Emergency Medicine

View full text Add to dashboard Cite

The network analysis identified IM corticosteroids and PO long-course corticosteroids as the most effective strategies to prevent relapse among adults with acute asthma, compared to PO short-course corticosteroids. The lack of significant findings with PO short-course corticosteroids is likely due to the paucity of research. Further comparative studies are required to determine the safety and effectiveness of briefer PO SCS treatment options in adults.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

“…The severity of the asthma exacerbation in the included patients was not reported in the majority of studies . Some studies summarized it as mild–moderate, moderate–severe, and severe…”

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

See 2 more Smart Citations

Prioritizing Systemic Corticosteroid Treatments to Mitigate Relapse in Adults With Acute Asthma: A Systematic Review and Network Meta‐analysis

Rowe

Kirkland

Vandermeer

et al. 2017

Academic Emergency Medicine

View full text Add to dashboard Cite

show abstract

“…The study [2] was designed as a noninferiority trial and dexamethasone in fact failed (albeit narrowly) to meet the prespecified parameters of non-inferiority.…”

mentioning

confidence: 99%

The potential danger of journal summary services

Freeth¹

2016

S Afr Med J

View full text Add to dashboard Cite

Reconsidering Dexamethasone for Antiemesis when Combining Chemotherapy and Immunotherapy

2021

View full text Add to dashboard Cite

Whether the immune suppressive action of glucocorticoid steroids, such as dexamethasone, might reduce the benefits of cancer immunotherapy has long been a concern. Observations that established tumor regressions in response to immune checkpoint inhibitors (ICIs) often persist, despite the use of steroids to mitigate ICI‐related autoimmune breakthrough, are not sufficiently reassuring, because these observations do not address the potential blunting of immune priming at the initiation of ICI therapy. With increasing indications for ICI in combination with chemotherapy, this issue merits reconsideration. Professional society guidance advises that dexamethasone should be used as first‐line prophylaxis for nausea and vomiting in patients receiving ICI and highly emetogenic chemotherapy combination regimens. Here, we review the availability of data on this subject and propose an alternative approach focused on the adoption of steroid minimization or sparing for prophylaxis of nausea until the underlying immune biology is better understood.

show abstract

A Randomized Controlled Noninferiority Trial of Single Dose of Oral Dexamethasone Versus 5 Days of Oral Prednisone in Acute Adult Asthma

Cited by 25 publications

References 21 publications

Prioritizing Systemic Corticosteroid Treatments to Mitigate Relapse in Adults With Acute Asthma: A Systematic Review and Network Meta‐analysis

Prioritizing Systemic Corticosteroid Treatments to Mitigate Relapse in Adults With Acute Asthma: A Systematic Review and Network Meta‐analysis

The potential danger of journal summary services

Reconsidering Dexamethasone for Antiemesis when Combining Chemotherapy and Immunotherapy

Contact Info

Product

Resources

About